PVd Versus Vd in NDMM Patients With RI

Study Purpose

This is a multicenter, randomized controlled, open-label study, and the purpose of this study is to compare the efficiency and safety of PVD regimen (Pomalidomide & Bortezomib & Dexamethasone) versus VD regimen (Bortezomib & Dexamethasone) in NDMM patients with RI. The main efficacy indicator is VGPR after 4 cycles of induction therapy.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years - 75 Years
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Initial diagnosis of symptomatic multiple myeloma (according to the International Myeloma Working Group [IMWG] diagnostic criteria) - Men and women aged ≥18 years and ≤75 years.
  • - Multiple myeloma patients with measurable M protein should meet at least one of the following three tests: 1) Serum M protein ≥10 g/L; 2) Urinary M protein ≥200 mg/24h; 3) In the case of abnormal serum free light chain ratio, the level of affected free light chain ≥100 mg/L.
  • - No prior treatment for multiple myeloma.
  • - ECOG score ≤2, and predicted survival ≥3 months.
  • - Clinically diagnosed multiple myeloma-related renal injury with calculated or measured creatinine clearance (CrCl)≥15 mL/min and < 60 mL/min (excluding patients undergoing dialysis).
The calculated CrCl should be calculated using the widely accepted formula (i.e. Cockcroft-gault formula) :([140-Age] × body weight [kg] / [72 × creatinine mg/dL]); If the subject is female, multiply the result by 0.85 (1mg/dL=88.4umol/L)
  • - Hematology: When myeloma cells < 50%, ANC≥1.0×109/L (including with g-CSF support) and PLT≥75×109/L; Myeloma cells ≥50%, any ANC and PLT≥30×109/L; Adjusted serum calcium level ≤3.4 mmol/L; Hemoglobin level ≥8 g/dL.
  • - For the use of symptomatic and supportive therapy only, the biochemical requirements of 6 and 7 achieved by non-myeloma treatment drugs can also be included in the group.
  • - Liver, heart and other major organs meet the requirements of the following laboratory examination indicators (conducted within 7 days before treatment): 1) Total bilirubin ≤ 1.5 times the upper limit of normal value (same age); 2) Aspartate aminotransferase (AST) and alanine transferine (ALT) ≤ 1.5 times the upper limit of normal value (same age); 3) myocardial enzymes < 2 times the upper limit of normal value; 4) Echocardiography (ECHO) determined that cardiac ejection fraction was within the normal range.
  • - Patients with inactive hepatitis and total bilirubin, AST and ALT meeting the inclusion criteria, but HBV-DNA≥104, are recommended to be treated with entecavir and other antiviral drugs, and the treatment course will be determined by researchers after their own evaluation of the patient's situation.
  • - Women of reproductive age (FCBP) subjects must have a negative serum pregnancy test 21 days prior to enrollment and consent to use a valid contraceptive method during all study medications and within 30 days after the last study medication (pregnancy tests may be performed more frequently if local guidelines are followed).
FCBP is defined in this protocol as sexually mature women who: 1) have not undergone hysterectomy, bilateral oophorectomy or bilateral salpingectomy, or 2) have not experienced spontaneous menopause for at least 24 consecutive months (i.e., have had menstruation at any time in the previous 24 consecutive months)
  • - If having sex with FCBP, male subjects must use an effective barrier method of contraception during the study period and for 3 months after the last study drug.
Male subjects were not allowed to donate sperm during treatment and for 90 days after the last study drug. Male subjects whose partners are pregnant must abstain from sex or use condoms during vaginal intercourse.
  • - Clearly understand the test content, voluntarily participate in and complete the test, and sign the informed consent.
Informed consent was signed by the patient himself or his immediate family. Considering the patient's condition, if the patient's signature is not conducive to treatment, the informed consent shall be signed by the legal guardian or the patient's immediate family member.
  • - Those who can receive and use antithrombotic drugs, such as low-molecular-weight heparin sodium or aspirin, etc.

    Exclusion Criteria:

    - Primary renal disease or secondary renal injury not related to multiple myeloma, such as diabetes.
  • - Prior treatment for myeloma (excluding radiation, bisphosphonates, or a single short-term hormone therapy [i.e., a 4-day dose less than or equivalent to dexamethasone 40mg/ day]) - Non-active multiple myeloma, including MGUS and smoking myeloma.
  • - Prior malignancies requiring treatment or with evidence of recurrence in the 5 years prior to the first study [excluding basal cell carcinoma of the skin and the following carcinomas in situ: Squamous cell carcinoma, carcinoma in situ of bladder, carcinoma in situ of endometrium, carcinoma in situ of cervix/dysplasia, occasional histological discovery of prostate cancer (TNM stage T1a or T1b) or carcinoma in situ of breast] - Patients with renal insufficiency accompanied by dialysis (excluding those who had received dialysis treatment due to renal insufficiency in the early stage but had not received anti-MM treatment and were not on dialysis at the time of enrollment) - Active hepatitis A, B, C infection or known HCV RNA positive.
  • - Known to be HIV positive.
  • - Active infections that are not under control.
  • - History of VTE or cerebral infarction before treatment.
  • - Patients had uncontrolled or severe cardiovascular disease, including myocardial infarction within 6 months prior to enrollment, NYHA defined class ⅲ - ⅳ heart failure, uncontrolled angina, congestive heart failure, clinically significant pericardial disease, or cardiac amyloidosis (NT-Pro-BNP≥1800pg/mL) - Patients who received major operations within 30 days before the enrollment, which would cause significant physical decline and increased risk of thrombosis, or the operations were scheduled during the study period.
Participants who planned to undergo surgery under local anesthesia that would not significantly affect the patient's physical performance or significantly increase the risk of thrombosis could participate in the study.
  • - The proportion of peripheral plasma cells ≥5%, and/or the absolute value of peripheral plasma cells ≥0.5×109/L.
  • - Subjects are pregnant or lactating women.
  • - Uncontrolled high blood pressure or uncontrolled diabetes.
  • - Allergic to borate, mannose, and thalidomide.
  • - According to the protocol or the investigator's judgment, the patient's serious physical or mental illness may interfere with the clinical study participation; Substance abuse, medical, psychological, or social conditions that may interfere with subjects' participation in the study or evaluation of study results.
  • - Patients receiving other experimental drugs.
  • - Participants in other clinical trials within one month.
- Any patients deemed unsuitable for inclusion by other investigators

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Phase 2
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

RenJi Hospital
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Jian Hou, PhD
Principal Investigator Affiliation RenJi Hospital
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Not yet recruiting

The disease, disorder, syndrome, illness, or injury that is being studied.

Multiple Myeloma
Arms & Interventions


Experimental: Pomalidomide, Bortezomib and Dexamethasone (PVD)

Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.

Active Comparator: Bortezomib and Dexamethasone (VD)

Each cycle is 21 days, after 2 cycles, patients who reached MR continued treatment for 2 cycles, 4 cycles in total. Subsequent treatment regimens after 4 cycles of induction therapy were determined by the investigator.


Drug: - pomalidomide

Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.

Drug: - Bortezomib

Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.

Drug: - Dexamethasone

Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.

Contact Information

This trial has no sites locations listed at this time. If you are interested in learning more, you can contact the trial's primary contact:

Jian Hou, PhD



For additional contact information, you can also visit the trial on clinicaltrials.gov.